Please select the option that best describes you:
Are you routinely recommending adjuvant ribociclib now for node-negative HR+/HER2- breast cancer given data from the NATALEE trial?
Is the data sufficient in the node-negative patient population?
Answer from: Medical Oncologist at Community Practice
Adjuvant ribociclib has demonstrated a significant benefit in node-negative (N0) patients with HR+/HER2− early breast cancer in the NATALEE trial, expanding its role beyond traditional high-risk, node-positive populations.NATALEE Trial: Ribociclib in Node-Negative (N0) PatientsEligibility for ...
Sign In or Register to read more
Answer from: Medical Oncologist at Community Practice
Yes, I offer eligible node-negative patients, as defined by the NATALEE trial criteria, with anatomic stage II or III hormone receptor-positive breast cancer node-negative patients who are at high risk of recurrence, as defined by and would have met criteria for the NATALEE trial.The NATALEE trial d...
Answer from: Medical Oncologist at Community Practice
If patients are meeting the criteria for NATALEE (T2 N0 Grade III, Ki67 >= 20% or high GEP risk defined as RS > 25 or MPI < 0), then I offer them adjuvant CDK4/6i per label. ESMO 2025 5-year analysis demonstrated:
Overall iDFS HR: 0.716 (95% CI 0.618–0.829)
5-year iDFS 85.5% vs 81.0...